Journal de la leucémie
Libre accès
ISSN: 2329-6917
ISSN: 2329-6917
Zheng Yan, Shuna Yao, Yanyan Liu*, Zhihua Yao*
Hepatitis B Virus Reactivation (HBV-R) is a potentially fatal complication in HBV-infected patients with hematological malignancies receiving immunosuppressive anticancer drugs. The risk of HBV-R has been well evaluated in the rituximab era. In recent years, an increasing number of novel anticancer drugs have been approved or under investigation for the treatmen11t of hematological malignancies. However, cumulative data on HBV-R in patients treated with these novel drugs are very scarce. This mini-review aims to summarize recently published data concerning HBV-R in patients with hematological malignancies receiving novel drugs. Data accumulated to date show that HBV-R is highly preventable and manageable in this population.